@Captain G
Either
Perforamnce shares tranches are HALVED in numbers,
or
Milestones (targets) DOUBLED to $200m to $500m MCap,
for fair play.
*Directors have insider knowledge abt
1)Deals that will be coming in the pipelines, esp what/why/when/who is "$7m for production"
2) " Imminent sales", Vsms,
3) Nmpa clearance expected in Q3 ( or Q4, latest ), which triggers $80m MOUs
4) Nasdaq listing in Q3
Milestones in this instance should be set by Independent Directors (which we dont have), not Yacov (CEO) , also chief benediciary, and largest SSHolder (45% voter, albeit he will abstain from voting on his perf.shares).
Fair play.
Not gifting.
I will vote against supergenerous perf.shares to Ycov and directors, for such low targets/milestones, esp $100m MCap which can easily be hit by any one of
item #2,3, or 4
very shortly.
( Retail shh votes will not beat those resolutions.
Any other ways?)
ps
*Raise targets to $200m_$500m,
or
Haive the Perf.shares tranches*
Pls * tell* Henry J @G13 and R15, if you contact him
Thx.
- Forums
- ASX - By Stock
- GMV
- Ann: Notice of Annual General Meeting
Ann: Notice of Annual General Meeting, page-63
-
- There are more pages in this discussion • 390 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online